

**Draft Performance Standards for Stably Transfected Transactivation
In Vitro Assays to Detect Estrogen Agonists (For TG 455)**

INTRODUCTION

1. The following Performance Standards (PS) accompanies the Performance Based Test Guideline for Transfected Transactivation *In Vitro* Assays to Detect Estrogen Agonists (for TG 455). This document is intended as a guide to developers of new test methods that are analogous to existing, fully validated test methods in that they are based on similar scientific principles and predict the same effect (colloquially referred to as “me too” tests) (1). Prior to the acceptance of a new test method for regulatory testing applications, validation studies are conducted using scientifically sound principles to establish its reliability (i.e., the extent of intra- and interlaboratory reproducibility over time when performed using the standardized protocol), and its relevance (i.e., the ability of the test method to correctly predict or measure the biological effect of interest) (1) (2) (3) (4). The purpose of the PS is to communicate the basis by which new proprietary (i.e. copyrighted, trademarked, registered) or nonproprietary test methods can be determined to have sufficient accuracy (i.e., agreement between a test method result and an accepted reference value) and reliability (i.e., extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol) for a specific testing purpose. Thus, this provides an avenue to demonstrate that a newly developed test method based on similar scientific principles has comparable or better performance capabilities than those from which the existing PS were derived, and may allow a more timely use of the new test method. New test methods (“me too” tests) can be added to TG 455 after OECD review and agreement that performance standards are met. A new test method developed under this PS will be covered by TG 455 only after TG 455 has been updated to add the new test method.

2. Performance standards are based on an adequately validated test method(s) and provide a basis for evaluating the comparability of a proposed test method that is mechanistically and functionally similar (1) (2). The three elements of performance standards are:

- Essential test method components: These consist of essential structural, functional, and procedural elements of a validated test method that should be included in the protocol of a proposed test method that is considered to be mechanistically and functionally similar to the validated method. Essential test method components include unique characteristics of the test method, critical procedural details, and quality control measures.

- A list of reference chemicals: Reference chemicals are used to assess the accuracy and reliability of a proposed mechanistically and functionally similar test method. These chemicals are a representative subset of those used to demonstrate the reliability and the accuracy of the validated test method, and are the minimum number that should be used to evaluate the performance of a proposed mechanistically and functionally similar test method.

- Accuracy and reliability performance values: These are the standards for accuracy (i.e., sensitivity, specificity, false positive/negative rates) and reliability (i.e., degree to which the test method can be performed reproducibly within and among laboratories over time) that the proposed test method should meet or exceed when evaluated using the minimum list of reference chemicals.

3. The fully validated reference test methods that provide the basis for this PS are:

- The Stably Transfected TA assay (STTA) using the human (h) ER α -HeLa-9903 cell line (5) and
- The BG1Luc ER TA assay (6) using the BG1Luc-4E2 cell line which predominately expresses hER α with some contribution from hER β (7) (8).

ESSENTIAL TEST METHOD COMPONENTS AND OTHER VALIDATION CONSIDERATIONS

4. Certain principles are important in delineating the essential test method components that determine whether transactivation (TA) tests are functionally and mechanistically similar. *In vitro* estrogen receptor (ER) TA assays are designed to identify substances that might interfere with ER-mediated cellular processes *in vivo*. The interaction of estrogens with cellular ER initiates a cascade of events leading to the expression of specific genes in multiple target tissues.

5. The following test method components may vary, so this PBTG does apply to test methods that may differ in
- cell type (e.g. mammalian, fish, yeast)
 - cell line (tissue type)
 - characteristics of the cell line including presence of other receptors and metabolism
 - culture conditions
 - plating density
 - plate layout (including how controls are incorporated)
 - ER α characteristics (full length or partial, species of origin); if other ER proteins are present, ER α should predominate and the relative expression of each receptor should be known
 - reporter gene construct (promoter, receptor binding elements, reporter)
 - method of determining cytotoxicity.
- These elements should be clearly described in each test method.

6. Essential test method components for *in vitro* ER TA protocols should include:
- The use of a strong reference estrogen, preferably 17 β -estradiol, to demonstrate the adequacy of the method for detecting ER agonists;
 - A weak positive control with a potency (e.g., PC₅₀, EC₅₀) two to five orders of magnitude lower than the reference estrogen should be included to provide another quality control measure by which to judge the acceptability of the method for detecting a weak agonist, and by which to evaluate the reproducibility of the test method.
 - A vehicle control (e.g., DMSO, EtOH, or H₂O) that is miscible with cell culture media at concentrations that are not cytotoxic and do not otherwise interfere with the test system.
 - A minimum limit concentration and at least seven concentrations spaced at decadic logarithmic (log₁₀) intervals should be tested up to the limit concentration.
 - In the absence of solubility or cytotoxicity restraints, the maximum concentration may be 1 mM or even up to the limit of solubility if appropriate.

- A qualitative or quantitative evaluation of cytotoxicity and how it is applied to the test method should be included in each study. Concentrations of test substances that clearly reduce viability should not be considered in the analysis of the data.

- All concentrations of the controls (e.g., vehicle, weak positive(s), or negative(s)), the reference estrogen, and the test substance should be tested in more than one replicate well.

7. No standardized statistical methods for analyzing data obtained from *in vitro* ER TA agonist assays have been developed. Each test method should establish a well-defined method for classifying a positive and a negative response. Where possible, positive results should be characterized by both the magnitude of the effect and the concentration at which the effect occurs (e.g., an EC₅₀, PC₅₀, % max, etc.).

8. To ensure that a proposed *in vitro* ER TA test method possesses characteristics similar to other validated test methods, the reference chemicals for testing ER agonists listed in Table 1 should be used to demonstrate the reliability and accuracy of the new test method. The twenty two recommended Reference Chemicals, representing chemical classes commonly associated with ER agonist activity, have been classified as ER agonists or negatives based upon published reports, including *in vitro* assays for ER binding and TA, and the *in vivo* uterotrophic assay (6) (9) (10) (11) (12) (13) (14) (15). The Reference Chemicals were tested in both the STTA and BG1Luc ER TA test methods (6) (9); the classifications (16 positive, 6 negative) were 100% concordant between the two test methods and consistent with the classifications as ER agonists or negatives, and the group of chemicals cover the potency range of known ER agonists (i.e., EC₅₀ 1 × 10⁻¹² M) to very weak (i.e., PC₁₀, EC₅₀ 1 × 10⁻⁵ M) to negative for ER agonist activity. Supplementary information including the full listings of chemicals tested in both the STTA and the BG1Luc ER TAs, as well as additional chemicals tested in each test method during the respective validation studies, is provided in Annex 2 (Tables 1, 2 and 3). Additional chemicals not included in the reference chemical list may be used to demonstrate an improvement of the new test method as compared with the fully validated test methods.

Table 1. List of Reference Chemicals (22) for Evaluation of ER Agonist Accuracy¹

Chemicals ^{1,2}	CASRN	Expected Reponse ^{1,3}	Bg1Luc EC ₅₀ Value ^{3,4,5} (M)	STTA and BG1Luc ER TA Results ^{4,5,7}	STTA ER TA ^{6,7}	
					PC ₁₀ Value (M)	PC ₅₀ Value (M)
Ethyl paraben	120-47-8	POS	2.48×10^{-5}	POS	5.00×10^{-6}	-
Kaempferol	520-18-3	POS	3.99×10^{-6}	POS	1.36×10^{-7}	1.21×10^{-6}
Butylbenzyl phthalate	85-68-7	POS	1.98×10^{-6}	POS	1.14×10^{-6}	4.11×10^{-6}
<i>p,p'</i> -Methoxychlor	72-43-5	POS	1.92×10^{-6}	POS	1.23×10^{-6}	-
19-Nortestosterone	434-22-0	POS	1.80×10^{-6}	POS	9.64×10^{-9}	2.71×10^{-7}
Bisphenol A	80-05-7	POS	5.33×10^{-7}	POS	2.02×10^{-8}	2.94×10^{-7}
Kepon	143-50-0	POS	4.91×10^{-7}	POS	7.11×10^{-7}	7.68×10^{-6}
4-Cumylphenol	599-64-4	POS	3.20×10^{-7}	POS	1.49×10^{-7}	1.60×10^{-6}
Genistein	446-72-0	POS	2.71×10^{-7}	POS	2.24×10^{-9}	2.45×10^{-8}
Coumestrol	479-13-0	POS	1.32×10^{-7}	POS	1.23×10^{-9}	2.00×10^{-8}
4- <i>tert</i> -Octylphenol	140-66-9	POS	3.19×10^{-8}	POS	1.85×10^{-9}	7.37×10^{-8}
17 α -Estradiol	57-91-0	POS	1.40×10^{-9}	POS	7.24×10^{-11}	6.44×10^{-10}
Norethynodrel	68-23-5	POS	9.39×10^{-10}	POS	1.11×10^{-10}	1.50×10^{-9}
Diethylstilbestrol	56-53-1	POS	3.34×10^{-11}	POS	$<1.00 \times 10^{-11}$	2.04×10^{-11}
<i>meso</i> -Hexestrol	84-16-2	POS	1.65×10^{-11}	POS	$<1.00 \times 10^{-11}$	2.75×10^{-11}
17 α -Ethinyl estradiol	57-63-6	POS	7.31×10^{-12}	POS	$<1.00 \times 10^{-11}$	$<1.00 \times 10^{-11}$
Atrazine	1912-24-9	NEG	-	NEG	-	-
Corticosterone	50-22-6	NEG	-	NEG	-	-
Linuron	330-55-2	NEG	-	NEG	-	-
Spiroinolactone	52-01-7	NEG	-	NEG	-	-
Ketoconazole	65277-42-1	NEG	-	NEG	-	-
Reserpine	50-55-5	NEG	-	NEG	-	-

Abbreviations: CASRN = Chemical Abstracts Service Registry Number; EC₅₀ – half maximal effective concentration; NEG = negative; PC₁₀ (and PC₅₀) = the concentration of a test chemical at which the response is 10% (or 50% for PC₅₀) of that induced by the positive controls (E2, 1nM); POS = positive.

¹Chemicals, classified as ER agonists or negatives [6, 9, 10-15], were selected to represent the different chemical classes and the range of potency from strong (i.e., EC₅₀ 1×10^{-12} M) to very weak (i.e., PC₁₀, EC₅₀ 1×10^{-5} M) to negative for ER agonist activity.

²See Annex 2 (Table 1) for chemical and product classes as assigned using the U.S. National Library of Medicine's Medical Subject Headings (MeSH), an internationally recognized standardized classification scheme (available at: <http://www.nlm.nih.gov/mesh>), and the U.S. National Library of Medicine's Hazardous Substances Database (available at: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB>).

³Expected responses and BG1Luc ER TA data compiled and reported in ICCVAM Test Method Evaluation Report on the LUMI-CELL[®] ER (BG1Luc ER TA) Test Method An *In Vitro* Method for Identifying ER Agonists and Antagonists [6].

⁴Mean EC₅₀ values were calculated with values reported by the laboratories of the BG1Luc ER TA validation study (XDS, ECVAM, and Hiyoshi).

⁵See draft proposal for new test guideline: BG1Luc Estrogen Receptor Transactivation Test Methods for identifying estrogen receptor agonist and antagonists, Table 4 for definitions of positive and negative classifications.

⁶See OECD TG 455: Stably Transfected Human Estrogen Receptor-alpha Transcriptional Activation Assay for Detection of Estrogenic Agonist-Activity of Chemicals, Table 5 for definitions of positive negative classifications [5].

⁷PC₁₀/PC₅₀ values reported in Draft Report of Pre-validation and Inter-laboratory Validation for Stably Transfected Transcriptional Activation (TA) Assay to Detect Estrogenic Activity - The Human Estrogen Receptor Alpha Mediated Reporter Gene Assay Using hER-HeLa-9903 Cell Line [9].

9. Metabolism of the reference chemicals in the cell system under development should be considered when assessing the results when testing the Reference Chemicals (Table 1). The degree of metabolic competence of the cell system may influence the qualitative (positive or negative) or quantitative (EC₅₀/PC₁₀) result. Metabolism of inactive chemicals to active chemicals, e.g., from DEHP (Bis (2-ethylhexyl) phthalate) into MEHP (Mono (2-ethylhexyl) phthalate), or from active chemicals to more active metabolites, e.g, metabolism of methoxychlor to HPTE (2,2-bis(*p*-hydroxyphenyl)-1,1,1-trichloroethane), or the conversion of estrone into 17β-estradiol, may result in lower EC₅₀/PC₁₀ values. However, the opposite may occur as well, e.g. inactivation of estradiol by hydroxylation, or in cell lines competent in Phase 2 metabolising enzymes the test chemicals may be metabolised to inactive glucuronide or sulphate conjugates. Ideally, the metabolic capability of the cell line should be characterised. However, the metabolic capabilities of the STTA and BG1Luc cell lines have not been completely characterised, and therefore, this should also be considered. For example, the positive result with benzyl butyl phthalate (Table 1) is thought to result from hydroxylation to monosubstituted phthalates. Thus, a cell line with a hydroxylase deficiency would give a negative result. These considerations are extremely important for QSAR modeling approaches, as it may not be the compound under investigation that is actually responsible for the observed response, but rather the metabolites formed.

10. New similar test methods should not be developed solely on the basis of the twenty two Reference Chemicals, but rather on a sufficiently large test development set. Reference chemicals should be preferentially used to determine equivalence of performance compared to the validated reference test methods.

11. All chemicals should be tested in a coded/blinded manner. When evaluated using these reference chemicals, the reliability and accuracy (i.e. sensitivity, specificity, false positive rates, and false negative rates) of the proposed ER TA test method should approximate the following:

DEFINED RELIABILITY AND ACCURACY VALUES

12. For purposes of establishing the reliability and relevance of the proposed similar or modified test method when transferred between laboratories, all twenty two Reference Chemicals (Table 1) should be tested in at least three laboratories. In each laboratory, all twenty two Reference Chemicals should be tested in three independent runs performed at sufficiently spaced time points.

13. The calculation of the reliability and accuracy values of the proposed new test method should be conducted following the three criteria below, ensuring that the values for reliability and relevance are calculated in a predefined and consistent manner:

1. Only the data of runs from complete run sequences qualify for the calculation of the test method within, and between-laboratory variability and predictive capacity (accuracy).
2. Only the data obtained for chemicals that have complete run sequences in all participating laboratories qualify for the calculation of the test method between-laboratory variability.
3. The calculation of the accuracy values should be done on the basis of the individual laboratory predictions obtained for the twenty two Reference Chemicals by the different participating laboratories.

In this context, a run sequence consists of three independent runs from one laboratory for one test chemical. A complete run sequence is a run sequence from one laboratory for one test chemical where all three runs are valid. This means that any single invalid run invalidates an entire run sequence of three runs.

Within-laboratory reproducibility

14. The assessment of within-laboratory reproducibility, the concordance of classifications (positive/negative) obtained in three independent test runs with each of the twenty two Reference Chemicals within a single laboratory, should be 100%.

Between-laboratory reproducibility

15. An assessment of between-laboratory reproducibility, the concordance classifications (positive/negative) obtained in three independent test runs with all or a subset of the 22 Reference Chemicals between preferentially a minimum of three laboratories, should be in the range of 83 - 100%.

Predictive capacity (accuracy)

16. The accuracy (sensitivity, specificity, positive and negative predictivity, and overall accuracy) of the proposed new similar or modified test method should be comparable to that demonstrated for these the fully validated test methods (e.g, STTA and BG1Luc ER TAs) (6) (9). On the basis of the twenty two reference chemicals (Table 1) tested in both fully validated reference methods, as well as other empirical data from these methods (see Annex 2), the target values for sensitivity, specificity, and overall accuracy to be obtained on the basis of the twenty two Reference Chemicals are set to be greater or equal to 95%.

17. Although it is not realistic to expect test methods to perform identically, discordant results should be discussed in terms of the ability of the test method to detect a similar range of potencies and chemical/product classes as demonstrated by the fully validated test methods (6) (9).

LITERATURE

1. OECD Guidance Document No. 34: Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. 2005, Paris:OECD Publishing.
2. ICCVAM. Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM). 1997. NIH Publication No. 97-3981. Research Triangle Park, NC:National Institute of Environmental Health Sciences.
3. ICCVAM. ICCVAM Guidelines for the Nomination and Submission of New, Revised, and Alternative Test Methods. 2003. NIH Publication No. 03-4508. Research Triangle Park, NC:National Institute of Environmental Health Sciences
4. OECD. Final Report of the OECD Workshop on Harmonization of Validation and Acceptance Criteria for Alternative Toxicological Test Methods. Paris:OECD Publishing.
5. OECD, Test No. 455: The Stably Transfected Human Estrogen Receptor-alpha Transcriptional Activation Assay for Detection of Estrogenic Agonist-Activity of Chemicals, in OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects. 2009, OECD Publishing: Paris. Available at: [<http://dx.doi.org/10.1787/9789264076372-en>]
6. ICCVAM, *ICCVAM Test Method Evaluation Report on the LUMI-CELL[®] ER (BG1Luc ER TA) Test Method An In Vitro Method for Identifying ER Agonists and Antagonists*. 2011, National Institute of Environmental Health Sciences: Research Triangle Park, NC.
7. Pujol, P., et al., Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. *Cancer Res*, 1998. 58(23): p. 5367-73.
8. Rogers, J.M. and M.S. Denison, Recombinant cell bioassays for endocrine disruptors: development of a stably transfected human ovarian cell line for the detection of estrogenic and anti-estrogenic chemicals. *In Vitro and Molecular Toxicology: Journal of Basic and Applied Research*, 2000. 13(1): p. 67-82.
9. Takeyoshi, M., *Draft Report of Pre-validation and Inter-laboratory Validation For Stably Transfected Transcriptional Activation (TA) Assay to Detect Estrogenic Activity - The Human Estrogen Receptor Alpha Mediated Reporter Gene Assay Using hER-HeLa-9903 Cell Line*. 2006, Chemicals Evaluation and Research Institute (CERI): Japan. p. 1-188.
10. ICCVAM (2003), ICCVAM Evaluation of *In Vitro* Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays. Available at: [<http://iccvam.niehs.nih.gov/methods/endocrine.htm#fineval>]; Addendum, 2006 [http://iccvam.niehs.nih.gov/docs/endo_docs/EDAddendFinal.pdf]
11. ICCVAM, Background Review Document: Estrogen Receptor Binding. Appendix D, Substances Tested in the ER Binding Assay, 2002. NIH Publication Report No. 03-4504. Available at: [http://iccvam.niehs.nih.gov/docs/endo_docs/final1002/erbnbrd/ERBd034504.pdf]
12. ICCVAM, Background Review Document: Estrogen Receptor Transcriptional Activation (TA)

22 December 2011

Assay. Appendix D, Substances Tested in the ER TA Assay, 2002. NIH Publication Report No. 03-4505. Available at: [http://iccvam.niehs.nih.gov/docs/endo_docs/final1002/erta_brd/ERTA034505.pdf]

13. Kanno, J, et al., The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: Phase 1. 2001, Environ Health Perspect. 109:785-94.
14. Kanno J, et al., The OECD program to validate the rat uterotrophic bioassay: Phase Two - Dose Response Studies. 2003, Environ. Health Persp. 111:1530-1549
15. Kanno J, et al., The OECD program to validate the rat uterotrophic bioassay: Phase Two – Coded Single Dose Studies. Environ. Health Persp. 111:1550-1558.

ANNEX 1

Definitions and Abbreviations

Acceptability criteria: Minimum standards for the performance of experimental controls and reference standards. All acceptance criteria must be met for an experiment to be considered valid.

Accuracy: (a) The closeness of agreement between a test method result and an accepted reference value. (b) The proportion of correct outcomes of a test method. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with “concordance” to mean the proportion of correct outcomes of a test method.

Agonist: A substance that produces a response, e.g., transcription, when it binds to a specific receptor.

BG-1: An immortalized adenocarcinoma cells that endogenously express estrogen receptor.

BG-1Luc4E2: The BG-1Luc4E2 cell line was derived from BG-1 immortalized human-derived adenocarcinoma cells that endogenously express both forms of the estrogen receptor (ER α and ER β) and have been stably transfected with the plasmid pGudLuc7.ERE. This plasmid contains four copies of a synthetic oligonucleotide containing the estrogen response element upstream of the mouse mammary tumor viral (MMTV) promoter and the firefly luciferase gene.

Cytotoxicity: the harmful effects to cell structure or function ultimately causing cell death and can be a result of a reduction in the number of cells present in the well at the end of the exposure period or a reduction of the capacity for a measure of cellular function when compared to the concurrent vehicle control.

CV: Coefficient of variation

DMSO: Dimethyl sulfoxide

E2: 17 β -estradiol

EC₅₀: The half maximal effective concentration of a test substance.

ER: Estrogen receptor

hER α : Human estrogen receptor alpha

hER β : Human estrogen receptor beta

ERE: Estrogen response element

Estrogenic activity: the capability of a chemical to mimic 17 β -estradiol in its ability to bind to and activate estrogen receptors. hER α -mediated specific estrogenic activity can be detected in this PBTG.

HeLa: An immortal human cervical cell line

HeLa9903: A HeLa cell subclone into which hER α and a luciferase reporter gene have been stably transfected

hER α : Human estrogen receptor alpha

hER β : Human estrogen receptor beta

LEC: Lowest effective concentration is the lowest concentration of test substance that produces a threshold response (*i.e.* the lowest test substance concentration at which the fold induction is statistically different from the concurrent vehicle control).

Interlaboratory reproducibility: A measure of the extent to which different qualified laboratories using the same protocol and testing the same substances can produce qualitatively and quantitatively similar results. Interlaboratory reproducibility is determined during the prevalidation and validation processes, and indicates the extent to which a test method can be transferred successfully among laboratories.

Intralaboratory reproducibility: The closeness of agreement between test results obtained within a single laboratory when the procedure is performed on the same substance under identical conditions within a given time period.

Me-too test: A colloquial expression for a test methods that is structurally and functionally similar to a validated and accepted reference test method. Such a test method would be a candidate for catch-up validation. Interchangeably used with similar test method.

PBTG: Performance-Based Test Guideline.

PC: Positive control (1 nM of E2)

PC₁₀: the concentration of a test chemical at which the measured activity in an agonist assay is 10% of the maximum activity induced by the PC (E2 at 1nM for the STTA assay) in each plate.

PC₅₀: the concentration of a test chemical at which the measured activity in an agonist assay is 50% of the maximum activity induced by the PC (E2 at the reference concentration specified in the test method) in each plate.

PC_{Max}: the concentration of a test chemical inducing the RPCMax

Performance standards: Standards, based on a validated test method, that provide a basis for evaluating the comparability of a proposed test method that is mechanistically and functionally similar. Included are (1) essential test method components; (2) a minimum list of reference substances selected from among the chemicals used to demonstrate the acceptable performance of the validated test method; and (3) the comparable levels of accuracy and reliability, based on what was obtained for the validated test method, that the proposed test method should demonstrate when evaluated using the minimum list of reference chemicals.

Proficiency chemicals (substances): A subset of the Reference Chemicals included in the Performance Standards that can be used by laboratories to demonstrate technical competence with a standardized test method. Selection criteria for these substances typically include that they represent the range of responses, are commercially available, and have high quality reference data available.

Proficiency: The demonstrated ability to properly conduct a test method prior to testing unknown substances.

Reference chemicals (substances): A set of chemicals to be used to demonstrate the ability of a new test method to meet the acceptability criteria demonstrated by the validated reference test method(s). These chemicals should be representative of the classes of chemicals for which the test methods is expected to be used, and should represent the full range of responses that may be expected from the chemicals for which it may be used, from strong, to weak, to negative.

Reference estrogen (Positive control, PC): The reference estrogen, 17 β -estradiol (E2, CAS 50-28-2).

Reference standard: a reference substance used to demonstrate the adequacy of a test method. 17 β -estradiol is the estrogenic reference standard for the STTA and BG1Luc ER TAs.

Reference test method: The test methods upon which this PBTG is based.

Relevance: Description of relationship of the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates consideration of the accuracy (concordance) of a test method.

Reliability: Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility.

RPCMax: maximum level of response induced by a test chemical, expressed as a percentage of the response induced by 1 nM E2 on the same plate

SD: Standard deviation.

Sensitivity: The proportion of all positive/active substances that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results, and is an important consideration in assessing the relevance of a test method.

Specificity: The proportion of all negative/inactive substances that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results, and is an important consideration in assessing the relevance of attest method.

Stable transfection: When DNA is transfected into cultured cells in such a way that it is stably integrated into the cells genome, resulting in the stable expression of transfected genes. Clones of stably transfected cells are selected by stable markers (e.g., resistance to G418).

STTA: Stably Transfected Transcriptional Activation Assay, the ER α transcriptional activation assay using the HeLA 9903 Cell Line.

Substance: Used in the context of the UN GHS (1) as chemical elements and their compounds in the natural state or obtained by any production process, including any additive necessary to preserve the stability of the product and any impurities deriving from the process used, but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition.

TA: Transactivation.

Transcription: mRNA synthesis

Transcriptional activation: The initiation of mRNA synthesis in response to a specific chemical signal, such as a binding of an estrogen to the estrogen receptor.

Validated (reference) test method: An accepted test method for which validation studies have been completed to determine the accuracy and reliability of the method for a specific proposed use.

Validation, a process based on scientifically sound principles by which the reliability and relevance of a particular test, approach, method, or process are established for a specific purpose. Reliability is defined as the extent of reproducibility of results from a test within and among laboratories over time, when performed using the same standardised protocol. The relevance of a test method describes the relationship between the test and the effect in the target species and whether the test method is meaningful and useful for a defined purpose, with the limitations identified. In brief, it is the extent to which the test method correctly measures or predicts the (biological) effect of interest, as appropriate (16).

VC (Vehicle control): The solvent that is used to dissolve test and control chemicals is tested solely as vehicle without dissolved chemical.

Weak positive control: A weakly active substance selected from the reference chemicals list that is included in all tests to help ensure proper functioning of the assay.

22 December 2011

ANNEX 2

Supplementary Information

for the

**Stably Transfected Human Estrogen Receptor- α Transcriptional Activation Assay for
Detection of Estrogenic Agonist-Activity of Chemicals using the hER α -HeLa-9903 cell line**

And

**BG1Luc Estrogen Receptor Transcriptional Activation Test Method for Identifying
Estrogen Receptor Agonists and Antagonists**

Table 1. Comparison of Results from STTA and BG1Luc ER TA Assays for Chemicals Tested in Both Assays and Classified as ER Agonists or Negatives.

Chemical	CASRN	STTA ER TA ¹			BG1Luc ER TA ²		Data Source For Classification ⁴			Chemical Class ⁵	Product Class ⁶
		ER TA Activity	PC ₁₀ Value (M)	PC ₅₀ Value ^b (M)	ER TA Activity	EC ₅₀ Value ^{b,3} (M)	Other ER TAs ^c	ER Binding	Uterotrophic		
17-β Estradiol ^a	50-28-2	POS	<1.00 × 10 ⁻¹¹	<1.00 × 10 ⁻¹¹	POS	5.63 × 10 ⁻¹²	POS (227/227)	POS	POS	Steroid	Pharmaceutical, Veterinary Agent
17-α Estradiol ^a	57-91-0	POS	7.24 × 10 ⁻¹¹	6.44 × 10 ⁻¹⁰	POS	1.40 × 10 ⁻⁹	POS(11/11)	POS	POS	Steroid	Pharmaceutical, Veterinary Agent
17-α Ethinyl estradiol ^a	57-63-6	POS	<1.00 × 10 ⁻¹¹	<1.00 × 10 ⁻¹¹	POS	4.20 × 10 ⁻⁸	POS(22/22)	POS	POS	Steroid	Pharmaceutical, Veterinary Agent
17-β-Trenbolone	10161-33-8	POS	1.78 × 10 ⁻⁸	2.73 × 10 ⁻⁷	POS	7.31 × 10 ⁻¹²	POS (2/2)	NT	NT	Steroid	Veterinary Agent
19-Nortestosterone ^a	434-22-0	POS	9.64 × 10 ⁻⁹	2.71 × 10 ⁻⁷	POS	1.80 × 10 ⁻⁶	POS(4/4)	POS	POS	Steroid	Pharmaceutical, Veterinary Agent
4-Cumylphenol ^a	599-64-4	POS	1.49 × 10 ⁻⁷	1.60 × 10 ⁻⁶	POS	3.20 × 10 ⁻⁷	POS(5/5)	POS	NT	Phenol	Chemical Intermediate
4- <i>tert</i> -Octylphenol ^a	140-66-9	POS	1.85 × 10 ⁻⁹	7.37 × 10 ⁻⁸	POS	3.19 × 10 ⁻⁸	POS(21/24)	POS	POS	Phenol	Chemical Intermediate
Apigenin ^a	520-36-5	POS	1.31 × 10 ⁻⁷	5.71 × 10 ⁻⁷	POS	1.60 × 10 ⁻⁶	POS(26/26)	POS	NT	Heterocyclic Compound	Dye, Natural Product, Pharmaceutical Intermediate
Atrazine ^a	1912-24-9	NEG	-	-	NEG	-	NEG (30/30)	NEG	NT	Heterocyclic Compound	Herbicide
Bisphenol A ^a	80-05-7	POS	2.02 × 10 ⁻⁸	2.94 × 10 ⁻⁷	POS	5.33 × 10 ⁻⁷	POS(65/65)	POS	POS	Phenol	Chemical Intermediate
Bisphenol B ^a	77-40-7	POS	2.36 × 10 ⁻⁸	2.11 × 10 ⁻⁷	POS	1.95 × 10 ⁻⁷	POS(6/6)	POS	POS	Phenol	Chemical Intermediate
Butylbenzyl phthalate ^a	85-68-7	POS	1.14 × 10 ⁻⁶	4.11 × 10 ⁻⁶	POS	1.98 × 10 ⁻⁶	POS(12/14)	POS	NEG	Carboxylic Acid, Ester, Phthalic Acid	Plasticizer, Industrial Chemical

22 December 2011

Chemical	CASRN	STTA ER TA ¹			BG1Luc ER TA ²		Data Source For Classification ⁴			Chemical Class ⁵	Product Class ⁶
		ER TA Activity	PC ₁₀ Value (M)	PC ₅₀ Value ^b (M)	ER TA Activity	EC ₅₀ Value ^{b,3} (M)	Other ER TAs ^c	ER Binding	Uterotrophic		
Corticosterone ^a	50-22-6	NEG	-	-	NEG	-	NEG(6/6)	NEG	NT	Steroid	Natural Hormone, Pharmaceutical
Coumestrol ^a	479-13-0	POS	1.23×10^{-9}	2.00×10^{-8}	POS	1.32×10^{-7}	POS(30/30)	POS	NT	Heterocyclic Compound	Natural Product
Daidzein ^a	486-66-8	POS	1.76×10^{-8}	1.51×10^{-7}	POS	7.95×10^{-7}	POS(39/39)	POS	POS	Flavonoid, Heterocyclic Compound	Natural Product
Diethylstilbestrol ^a	56-53-1	POS	$<1.00 \times 10^{-11}$	2.04×10^{-11}	POS	3.34×10^{-11}	POS(42/42)	POS	NT	Hydrocarbon (Cyclic)	Pharmaceutical, Veterinary Agent
Di-n-butyl phthalate	84-74-2	POS	4.09×10^{-6}		POS	4.09×10^{-6}	POS(6/11)	POS	NEG		Plasticizer, Chemical Intermediate
Ethyl paraben	120-47-8	POS	5.00×10^{-6}	(no PC ₅₀)	POS	2.48×10^{-5}	POS ()		NT	Carboxylic Acid, Phenol	Pharmaceutical, Preservative
Estrone ^a	53-16-7	POS	3.02×10^{-11}	5.88×10^{-10}	POS	2.34×10^{-10}	POS(26/28)	POS	POS	Steroid	Pharmaceutical, Veterinary Agent
Genistein ^a	446-72-0	POS	2.24×10^{-9}	2.45×10^{-8}	POS	2.71×10^{-7}	POS(100/102)	POS	POS	Flavonoid, Heterocyclic Compound	Natural Product, Pharmaceutical
Haloperidol	52-86-8	NEG	-	-	NEG	-	NEG (2/2)	NEG	NT	Butyrophenone	Pharmaceutical
Kaempferol ^a	520-18-3	POS	1.36×10^{-7}	1.21×10^{-6}	POS	3.99×10^{-6}	POS(23/23)	POS	NT	Flavonoid, Heterocyclic Compound	Natural Product
Kepone ^a	143-50-0	POS	7.11×10^{-7}	7.68×10^{-6}	POS	4.91×10^{-7}	POS(14/18)	POS	NT	Hydrocarbon, (Halogenated)	Pesticide
Ketoconazole	65277-42-1	NEG	-	-	NEG	-	NEG (2/2)	NEG	NT		Pharmaceutical
Linuron ^a	330-55-2	NEG	-	-	NEG	-	NEG (8/8)	NEG	NT	Phenylurea	Herbicide
<i>meso</i> -Hexestrol ^a	84-16-2	POS	$<1.00 \times 10^{-11}$	2.75×10^{-11}	POS	1.65×10^{-11}	POS(4/4)	POS	NT	Steroid	Pharmaceutical, Veterinary Agent

22 December 2011

Chemical	CASRN	STTA ER TA ¹			BG1Luc ER TA ²		Data Source For Classification ⁴			Chemical Class ⁵	Product Class ⁶
		ER TA Activity	PC ₁₀ Value (M)	PC ₅₀ Value ^b (M)	ER TA Activity	EC ₅₀ Value ^{b,3} (M)	Other ER TAs ^c	ER Binding	Uterotrophic		
Methyl testosterone ^a	58-18-4	POS	1.73×10^{-7}	4.11×10^{-6}	POS	2.68×10^{-6}	POS(5/6)	POS	NT	Steroid	Pharmaceutical, Veterinary Agent
Morin	480-16-0	POS	5.43×10^{-7}	4.16×10^{-6}	POS	2.37×10^{-6}	POS(2/2)	POS	NT	Flavonoid, Phenol	Natural product
Norethynodrel ^a	68-23-5	POS	1.11×10^{-11}	1.50×10^{-9}	POS	9.39×10^{-10}	POS(5/5)	POS	NT	Steroid	Pharmaceutical, Veterinary Agent
<i>p,p'</i> -Methoxychlor ^a	72-43-5	POS	1.23×10^{-6}	(no PC ₅₀) ^b	POS	1.92×10^{-6}	POS(24/27)	POS	POS	Hydrocarbon (Halogenated)	Pesticide, Veterinary Agent
Phenobarbital ^a	57-30-7	NEG	-	-	NEG	-	NEG(2/2)	NEG	NT		Pharmaceutical, Analgesic
Reserpine	50-55-5	NEG	-	-	NEG	-	NEG(4/4)	NEG	NT	Heterocyclic Compound, Indole	Pharmaceutical, Veterinary Agent
Spirolactone ^a	52-01-7	NEG	-	-	NEG	-	NEG(4/4)	NEG	NT	Lactone, Steroid	Pharmaceutical
Testosterone	58-22-0	POS	2.82×10^{-8}	9.78×10^{-6}	POS	1.75×10^{-5}	POS(5/10)	POS	NT	Steroid	Natural Hormone

Abbreviations: CASRN = Chemical Abstracts Service Registry Number; M = molar; EC₅₀ = half maximal effective concentration of test chemical; NEG = negative; POS = positive; PC₁₀ (and PC₅₀) = the concentration of a test chemical at which the response is 10% (or 50 % for PC₅₀) of the response induced by the positive control (E2, 1nM) in each plate.

^aCommon chemicals tested in the STTA ER TA and BG1Luc ER TA that were designated as definitive ER Agonists or negatives and used to evaluate accuracy in the BG1 Luc ER TA validation study (ICCVAM BG1Luc ER TA Evaluation Report, Table 4-1 [6].

^bMaximum concentration tested in the absence of limitations due to cytotoxicity or insolubility was 1×10^{-5} M (STTA ER TA) and 1×10^{-3} M (BG1Luc ER TA).

^cNumber in parenthesis represents the test results classified as positive (POS) or negative (NEG) over the total number of referenced studies.

¹Values reported in Draft Report of Pre-validation and Inter-laboratory Validation For Stably Transfected Transcriptional Activation (TA) Assay to Detect Estrogenic Activity - The Human Estrogen Receptor Alpha Mediated Reporter Gene Assay Using hER-HeLa-9903 Cell Line [9].

²ICCVAM Test Method Evaluation Report on the LUMI-CELL[®] ER (BG1Luc ER TA) Test Method: An *In Vitro* Method for Identifying ER Agonists and Antagonists [6].

³Mean EC₅₀ values were calculated with values reported by the laboratories of the BG1Luc ER TA validation study (XDS, ECVAM, and Hiyoshi) [6].

22 December 2011

⁴Classification as an ER agonist or negative was based upon information in the ICCVAM Background Review Documents (BRD) for ER Binding and TA test methods (31) as well as information obtained from publications published and reviewed after the completion of the ICCVAM BRDs [6, 9, 10, 11, 12, 13, 14, 15].

⁵Substances were assigned into one or more chemical classes using the U.S. National Library of Medicine's Medical Subject Headings (MeSH), an internationally recognized standardized classification scheme (available at: <http://www.nlm.nih.gov/mesh>).

⁶Substances were assigned into one or more product classes using the U.S. National Library of Medicine's Hazardous Substances Database (available at: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB>)

Table 2: Chemicals tested in the STTA ER TA Validation Study [9].

Chemical name	CASRN	STTA ER TA Classification ²			
		PC ₁₀ (M)	PC ₅₀ (M)	PC ₁₀	PC ₅₀
17β-Estradiol	50-28-2	<1.00 × 10 ⁻¹¹	<1.00 × 10 ⁻¹¹	P	P
17β-Trenbolone	10161-33-8	1.78E-08	2.73E-07	P	P
17α-Estradiol	57-91-0	7.24E-11	6.44E-10	P	P
17α-Ethinyl estradiol	57-63-6	<1.00 × 10 ⁻¹¹	<1.00 × 10 ⁻¹¹	P	P
2-sec-Butylphenol	89-72-5	-	-	N	N
4-Cumylphenol	599-64-4	1.49E-07	1.60E-06	P	P
4-tert-Octylphenol	140-66-9	1.85E-09	7.37E-08	P	P
Apigenin	520-36-5	1.31E-07	5.71E-07	P	P
Bisphenol A	80-05-7	2.02E-08	2.94E-07	P	P
Bisphenol B	77-40-7	2.36E-08	2.11E-07	P	P
Butylbenzyl phthalate	85-68-7	1.14E-06	4.11E-06	P	P
Coumestrol	479-13-0	1.23E-09	2.00E-08	P	P
Daidzein	486-66-8	1.76E-08	1.51E-07	P	P
Di-n-butyl phthalate	84-74-2	-	-	N	N
Diethylstilbestrol	56-53-1	<1.00 × 10 ⁻¹¹	2.04E-11	P	P
Estrone	53-16-7	3.02E-11	5.88E-10	P	P
Ethyl paraben	120-47-8	5.00E-06	(no PC50)	P	N
Flavone	525-82-6	2.26 × 10 ⁻⁶	-	P	N
Genistein	446-72-0	2.24E-09	2.45E-08	P	P
Kaempferol	520-18-3	1.36E-07	1.21E-06	P	P
Kepone (Chlordecone)	143-50-0	7.11E-07	7.68E-06	P	P
meso-Hexestrol	84-16-2	<1.00 × 10 ⁻¹¹	2.75 × 10 ⁻¹¹	P	P
Methyl testosterone	58-18-4	1.73E-07	4.11E-06	P	P
Morin	480-16-0	5.43E-07	4.16E-06	P	P
Norethynodrel	68-23-5	1.11E-10	1.50E-09	P	P
p-n-Nonylphenol	104-40-5	-	-	N	N
p,p'-Methoxychlor	72-43-5	1.23E-06	(no PC50)	P	N
Phenolphthalin	81-90-3	-	-	N	N
Progesterone	57-83-0	-	-	N	N
Testosterone	58-22-0	2.82E-08	9.78E-06	P	P
2,4,5-Trichloro-phenoxyacetic acid	93-76-5	-	-	N	N
Atrazine	1912-24-9	-	-	N	N
Corticosterone	50-22-6	-	-	N	N
Cyproterone acetate	427-51-0	-	-	N	N
Haloperidol	52-86-8	-	-	N	N
Ketoconazole	65277-42-1	-	-	N	N
L-Thyroxine	51-48-9	1.32E-06	(no PC50)	P	N

22 December 2011

Chemical name	CASRN	STTA ER TA Classification ²			
		PC ₁₀ (M)	PC ₅₀ (M)	PC ₁₀	PC ₅₀
Mifepristone	84371-65-3	-	-	N	N
Phenobarbital (Na salt)	57-30-7	-	-	N	N
Reserpine	50-55-5	-	-	N	N
Spirolactone	52-01-7	-	-	N	N
Vinclozolin	50471-44-8	1.33E-07	7.65E-06	P	P
Zearalenone	17924-92-4	2.44E-11	6.44E-10	P	P
Tamoxifen	10540-29-1	1.49E-07	(no PC50)	P	N
Diethylhexyl phthalate	117-81-7	-	-	N	N
4-Androstenedione	63-05-8	2.56E-07	(no PC50)	P	N
Flutamide	13311-84-7	-	-	N	N
Procymidone	32809-16-8	-	-	N	N
Clomiphene citrate	50-41-9	3.68E-08	(no PC50)	P	N

Abbreviations: Abbreviations: CASRN = Chemical Abstracts Service Registry Number; EC₅₀ – half maximal effective concentration; NEG = negative; PC₁₀ (and PC₅₀) = the concentration of a test chemical at which the response is 10% (or 50% for PC₅₀) of that induced by the positive controls (E2, 1nM); POS = positive.

¹The classification for this substance is “presumed positive” for ER agonism since the substance was positive in 50% or less of reported studies, or was reported positive in the single study conducted.

¹ICCCVAM, 2003. Evaluation of in vitro test methods for detecting potential endocrine disruptors: estrogen receptor and androgen receptor binding and transcriptional activation assays. NIH Publication No. 03-4503. Available at: [<http://iccvam.niehs.nih.gov/methods/endodocs/edfinrpt/edfinrpt.pdf>], Addendum, 2006: [10].

²Takeyoshi, M, Draft Report of Pre-validation and Inter-laboratory validation for stably transfected activation (TA) assay to detect estrogenic activity; The human estrogen receptor alpha mediated reporter gene assay using hER-HeLA-9902 cell line. 2006 [9].

Chemicals Evaluation and Research Institute (CERI): Japan, p. 1-188.

Table 3. Chemicals Tested during the BG1Luc ER TA Validation Study [6].

Substance	CASRN	BG1Luc ER TA Classification ¹
17 β -Estradiol	50-28-2	POS
17 β -Trenbolone	10161-33-8	POS
17 α -Estradiol	57-91-0	POS
17 α -Ethinyl estradiol	57-63-6	POS
19-Nortestosterone	434-22-0	POS
2-sec-Butylphenol	89-72-5	POS
4-Cumylphenol	599-64-4	POS
4-Hydroxy-androstenedione	566-48-3	POS
4-tert-Octylphenol	140-66-9	POS
Apigenin	520-36-5	POS
Bisphenol A	80-05-7	POS
Bisphenol B	77-40-7	POS
Butylbenzyl phthalate	85-68-7	POS
Chrysin	480-40-0	POS
Coumestrol	479-13-0	POS
Daidzein	486-66-8	POS
Di- <i>n</i> -butyl phthalate	84-74-2	POS
Dicofol	115-32-2	POS
Diethylstilbestrol	56-53-1	POS
Estrone	53-16-7	POS
Ethyl paraben	120-47-8	POS
Fenarimol	60168-88-9	POS
Flavone	525-82-6	POS
Fluoranthene	206-44-0	POS
Fluoxymestron	76-43-7	POS
Genistein	446-72-0	POS
Kaempferol	520-18-3	POS
Kepone	143-50-0	POS
meso-Hexestrol	84-16-2	POS
Methyl testosterone	58-18-4	POS
Morin	480-16-0	POS
Nilutamide	63612-50-0	POS
Norethynodrel	68-23-5	POS
<i>o,p'</i> -DDT	789-02-6	POS
<i>p-n</i> -Nonylphenol	104-40-5	POS
<i>p,p'</i> -Methoxychlor	72-43-5	POS
Phenolphthalin	81-90-3	POS
Progesterone	57-83-0	POS
Testosterone	58-22-0	POS

Substance	CASRN	BG1Luc ER TA Classification ¹
12- <i>O</i> -Tetradecanoylphorbol-13-acetate	16561-29-8	NEG
2,4,5-Trichloro-phenoxyacetic acid	93-76-5	NEG
4-Hydroxytamoxifen	68047-06-3	NEG
Actinomycin D	50-76-0	NEG
Ammonium perchlorate	7790-98-9	NEG
Apomorphine	58-00-4	NEG
Atrazine	1912-24-9	NEG
Bicalutamide	90357-06-5	NEG
Corticosterone	50-22-6	NEG
Cyproterone acetate	427-51-0	NEG
Dibenzo[<i>a,h</i>] Anthracene	53-70-3	NEG
Finasteride	98319-26-7	NEG
Haloperidol	52-86-8	NEG
Hydroxy flutamide	52806-53-8	NEG
Ketoconazole	65277-42-1	NEG
L-Thyroxine	51-48-9	NEG
Linuron	330-55-2	NEG
Medroxyprogesterone acetate	71-58-9	NEG
Mifepristone	84371-65-3	NEG
Phenobarbital	50-06-6	NEG
Pimozide	2062-78-4	NEG
Propylthiouracil	51-52-5	NEG
Raloxifene HCl	82640-04-8	NEG
Reserpine	50-55-5	NEG
Sodium azide	26628-22-8	NEG
Spirolactone	52-01-7	NEG
Vinclozolin	50471-44-8	NEG

Table is sorted by classification and then alphabetically by substance name.

¹ICCVAM Test Method Evaluation Report on the LUMI-CELL[®] ER (BG1Luc ER TA) Test Method An In Vitro Method for Identifying ER Agonists and Antagonists [6].

Table 4. Summary of the Reliability and Accuracy Values Obtained for the STTA and BG1Luc TAs: Validation Studies.

Place holder: Data to be added for Intra- and Intra-laboratory reproducibility, Sensitivity, Specificity, Positive and Negative predictivity, and Overall Accuracy values from respective validation studies.